Skip to main content
. 2022 Apr 6;5(4):e226114. doi: 10.1001/jamanetworkopen.2022.6114

Figure 1. Study Flow Diagram.

Figure 1.

Initial records search was performed for patients who had (1) hematologic cancer, (2) age between 8 and 70 years, (3) a low-dose antithymocyte globulin–based haploidentical hematopoietic stem cell transplant (HSCT), and (4) a transplant date between May 2012 and May 2021. A total of 788 records were identified and screened for patients with (1) minimal residual disease–negative during complete remission after haploidentical HSCT, (2) engraftment with 100% donor chimerism after haploidentical HSCT, (3) bone marrow hematologic relapse of minimal residual disease–positive, and (4) donor chimerism less than 97%. HLA indicates human leukocyte antigen.